Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French public sceptical of pharma but still has faith in medicines after Mediator scandal

This article was originally published in Scrip

Executive Summary

It cannot come as much of a surprise, -in the wake of the Mediator scandal that has gripped France, that the French public believes that the pharmaceutical industry is more concerned about profit than sick patients, according to a study conducted by the French R&D-based industry association, Leem. Nevertheless, reassuringly for industry, patients still trust in their medicines.

You may also be interested in...



What To Consider For German Orphan Drug Price Negotiations

The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.

Canada Counters Drug Shortages With Export Bans

Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.

The COVID-19 Economic Crisis – Fallout And Opportunities

In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel